子宫肉瘤粉碎术与生存:挪威全国注册研究
该研究基于挪威全国注册数据,比较1953–2012年诊断的子宫肉瘤患者中行粉碎术与否的生存差异,主要分析1991–2012年。结果显示粉碎术组肉瘤死亡率更高(年龄调整HR 1.90,95%CI 1.05–3.44),10年肉瘤生存率32.2% vs 57.2%。结论提示粉碎术可能损害意外子宫肉瘤患者的生存。
要点
- 粉碎术组年龄调整肉瘤死亡HR为1.90(95%CI 1.05–3.44)。
- 粉碎术组10年肉瘤生存率32.2%,非粉碎术组57.2%。
- 腹腔镜子宫切除术中子宫肉瘤患病率为3.6/1000。
核心结论
- 子宫切除术中粉碎术可能损害意外子宫肉瘤患者的生存。
- 结果可指导临床共同决策。
研究设计与样本
- 基于挪威全国注册的回顾性队列研究,纳入1953–2012年诊断的子宫肉瘤患者。
- 共1367例子宫肉瘤患者,其中653例诊断于1991年后,23例(3.5%)接受粉碎术。
- 主要比较1991–2012年粉碎术与非粉碎术患者的年龄调整疾病特异性生存。
主要发现
- 粉碎术组肉瘤死亡率高于非粉碎术组(年龄调整HR 1.90,95%CI 1.05–3.44)。
- 多因素HR为2.50(95%CI 0.57–10.9)。
- 粉碎术组年龄调整10年肉瘤生存率为32.2%,非粉碎术组为57.2%(差异25.5%,95%CI -55.7至18.1)。
- 粉碎术组10年全因生存率为32.2%,非粉碎术组为44.1%(差异11.9%,95%CI -40.9至32.7)。
- 粉碎术组平均随访6.0年,非粉碎术组6.9年;粉碎术后死于子宫肉瘤的风险为1.5/1000例手术。
临床怎么用
- 在腹腔镜或阴式子宫切除术中,对意外子宫肉瘤患者应谨慎评估粉碎术的使用。
- 粉碎术可能影响预后,需与患者进行共同决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is concern but no solid evidence that morcellation during laparoscopic or vaginal hysterectomy may cause abdominal spread and thereby impaired prognosis of incidental uterine sarcomas. OBJECTIVE: Our purpose was to compare survival among patients with uterine sarcomas who underwent hysterectomy with or without morcellation to test the hypothesis that morcellation impairs prognosis. STUDY DESIGN: We identified all women in Norway diagnosed with uterine sarcoma between 1953 and 2012 through national registries and retrieved data on surgical technique and morcellation by evaluation of patient files. Patients were categorised into abdominal, laparoscopic or vaginal hysterectomy with or without morcellation. Vaginal and laparoscopic hysterectomies were introduced in 1991; our main comparison is from 1991 to 2012. We compared age-adjusted disease-specific survival of sarcoma patients treated with or without morcellation and calculated age-adjusted hazard ratios (HRs) and subdistribution HR (accounting for competing risk) with 95% confidence intervals (CIs). RESULTS: Among 1367 patients with uterine sarcoma between 1953 and 2012 in Norway, 653 were diagnosed after 1991, and 23 of these patients (3.5%) underwent morcellation. Uterine sarcoma prevalence was 3.6 per 1000 laparoscopic hysterectomies. Mean follow-up was 6.0 years in the morcellated group and 6.9 years in the non-morcellated group. The risk of dying from uterine sarcoma after morcellation was 1.5 per 1000 procedures. Sarcoma mortality was higher in the morcellated group than in the non-morcellated group (age-adjusted HR 1.90, CI 1.05-3.44; multivariate HR, 2.50, 95% CI 0.57-10.9). Age-adjusted 10-year uterine sarcoma survival was 32.2% for women treated with morcellation compared with 57.2% for non-morcellated group (difference 25.5%; CI -55.7 to 18.1). All-cause 10-year survival was 32.2% in the morcellated group and 44.1% in the non-morcellated group (difference 11.9%; CI -40.9 to 32.7). CONCLUSION: Our results strengthen the evidence that morcellation during hysterectomy in patients with incidental uterine sarcoma may cause impaired survival. These results can guide shared decision-making in clinical practice.
引用
- Bretthauer M, Goderstad JM, Løberg M, et al. Uterine morcellation and survival in uterine sarcomas. Eur J Cancer. 2018. PMID: 30025231. doi:10.1016/j.ejca.2018.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。